C

Catalyst Biosciences Inc
F:HGF2

Watchlist Manager
Catalyst Biosciences Inc
F:HGF2
Watchlist
Price: 7.404 EUR 1 377.84% Market Closed
Market Cap: 279.6m EUR

Operating Margin
Catalyst Biosciences Inc

-3 703.7%
Current
-1 724%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-3 703.7%
=
Operating Profit
-29.4m
/
Revenue
794k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Catalyst Biosciences Inc
F:HGF2
279.6m EUR
-3 704%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
330.5B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
164.4B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
137.2B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.8B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
127.5B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.7B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Catalyst Biosciences Inc
Glance View

Market Cap
279.6m EUR
Industry
Biotechnology

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 45 full-time employees. The company went IPO on 2006-04-12. The firm is focused on developing protease therapeutics to address unmet medical needs in disorders of the complement system or where complement components are associated with the progression of the disease state. Its pipeline consists of a preclinical complement component 3 (C3) degrader program for geographic atrophy (GA) in dry age-related macular degeneration (dAMD), an improved Complement Factor I (CFI) protease, CB 4332, for subcutaneous (SQ) or intravitreal (IVT) therapy to restore complement homeostasis in diseases of overactive complement or CFI deficiencies, and proteases from our ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target specific disorders of the complement or inflammatory pathways. The Company’s portfolio consists of development candidates, which include CB 4332 and CB 2782-PEG.

HGF2 Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-3 703.7%
=
Operating Profit
-29.4m
/
Revenue
794k
What is the Operating Margin of Catalyst Biosciences Inc?

Based on Catalyst Biosciences Inc's most recent financial statements, the company has Operating Margin of -3 703.7%.

Back to Top